Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has ...

Lensar (LNSR) reached an agreement with Alcon (ALC) to terminate its planned sale. The parties are abandoning the deal as the ...

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the ...

Lensar (Nasdaq:LNSR) announced today that it reached an agreement with Alcon (NYSE:ALC) to terminate their planned merger.

Lensar today entered into a priority credit line agreement in a move that analysts say casts doubt over its planned acquisition by Alcon.

One medtech analyst raises concerns that Lensar's acquisition by Alcon is in trouble due to the company's recent priority ...

Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell. TruBridge said it would delay its fourth-quarter earnings ...

Staar Surgical reported a $80.4M full-year loss and 23.7% revenue decline, with analysts maintaining hold ratings as the ...

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by ...

Why Alcon Stock Is On Investors’ Radar Today Alcon (SWX:ALC) is back in focus after recent share price moves, with the stock showing mixed returns across different time frames and attracting fresh ...

Lensar, a medical technology company, said Monday the companies ended their agreement because they didn't expect to receive the necessary U.S. regulatory approvals in time to close the deal. The ...